Your gift is 100% tax deductible.
Targeted Drug Therapy for Adrenal Cancers
Targeted drugs focus on specific parts of cancer cells. Some targeted drugs might be useful for treating adrenal cancers that are advanced, cannot be removed by surgery, have spread, or have come back after treatment.
Targeted drugs are most often used to treat advanced pheochromocytomas. However, cabozantinib is also used to treat advanced adrenocortical carcinoma.
Learn more about targeted drug therapy to treat neuroblastoma in Targeted Drug Therapy for Neuroblastoma.
Kinase inhibitors
Kinases are proteins in or on cells that send signals to the rest of the cell. Sometimes they can help cells grow. Drugs called kinase inhibitors can help stop or slow the growth of some tumors. Examples of kinase inhibitors that might be used for certain adrenal cancers include:
- Cabozantinib (Cabometyx, Cometriq)
- Sunitinib (Sutent)
- Selpercatinib (Retevmo)
Selpercatinib is useful only if an adrenal cancer has a RET gene fusion.
These medications are taken by mouth as pills, typically once or twice a day.
Side effects of kinase inhibitors
Common side effects of kinase inhibitors include:
- Swelling
- High blood pressure
- Skin rash
- Belly pain
- Nausea
- Constipation or diarrhea
- Low appetite
- Low blood counts
- Low energy
- Muscle or joint pain
These medications can also have rare, but serious side effects. These include liver failure, heart problems, lung problems, bleeding, thyroid problems, and allergic type reactions.
Your care team will monitor you closely. If side effects occur, you might need to take a lower dose or stop the medication.
HIF-2α inhibitor
Belzutifan (Welireg) is a targeted therapy called a hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor. It works by blocking the HIF-2a protein.
This protein normally works with other proteins to increase blood flow when oxygen levels are low. Cancer cells rely on these signals to get the nutrients and oxygen they need to grow. When the signals are blocked, tumor growth may slow or stop.
This drug is especially useful for people who have tumors from von Hippel-Lindau syndrome, but it can be used for some tumors in people without it.
This medication is taken by mouth as a tablet once a day.
Side effects of HIF-2α inhibitors
Side effects of this medication may include:
- Swelling
- Constipation or diarrhea
- Nausea or vomiting
- Low appetite
- Low red blood cell count (anemia)
- Dizziness
- Low energy
- Muscle or joint pain
Your care team will monitor you closely. If side effects occur, you might need to take a lower dose or stop the medication.
- Written by
- References
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Fishbein L, Del Rivero J, Else T, et al. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021;50(4):469-493.
Louise M Binderup M, Smerdel M, Borgwadt L, et al. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. Eur J Med Genet. 2022;65(8):104538.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors Version 1.2026 – April 21, 2026. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf on June 23, 2026.
Young WF. Management of malignant (metastatic) paraganglioma and pheochromocytoma. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/management-of-malignant-metastatic-paraganglioma-and-pheochromocytoma on June 23, 2026.
Last Revised: October 5, 2026
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
American Cancer Society Emails
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.


